Promising data from our HBV program presented at EASL Congress

Thanks EASL for a great meeting and also the opportunity to simultaneously show data from our HBV program, both with regard to its robust preclinical proof of concept data package as well as the hot off the press interim clinical data from the ongoing Ph1b study. Very excited to see the excellent safety data and the impressive durability of our drug following only 1 or 2 doses s.c. injection and already at mid-dose level achieved profound HBsAg suppression, indeed supporting the dosing regime planned for the upcoming Ph2 study, where we anticipate even greater efficacy and durability, based on existing preclinical and clinical evidence.

Our HBV program is a siRNA molecule based on our proprietary Ribo-GalSTAR technology to combat chronic hepatitis B virus infection, a disease still causing huge mortality and morbidity for millions of patients around the world.

Share on social media

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website,
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
Contact information to the Data Protection Officer (DPO):
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal